Pharmacoeconomic Impact of the Sunitinib Adverse Events (AEs) Prophylaxis Treatment in Spain

Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib

“…A Spanish study of costs derived from the management of sunitinib-related AE demonstrated that procedures to avoid AE worsening from Grade 1 or 2 to Grade 3 or 4 (moderate or serious) will decrease the cost per patient, and also will lead to savings for the health system [36]. Thus, an appropriate prophylaxis and management of AE may influence both patients' quality of life and treatment-related costs.…”